A majority of volunteers with liver damage due to hepatitis C virus (HCV) infection were cured following a six-month course of therapy that combined an experimental drug, sofosbuvir, with the licensed antiviral drug ribavirin, in a study of an all-oral drug regimen. The results showed that the regimen was highly effective in clearing the virus and well tolerated in a group of patients who historically have had unfavorable prognoses. Scientists from the National ...Wednesday, 28 August 2013
NIH Trial Reveals Oral Regimen for Hepatitis C Shows Promise
A majority of volunteers with liver damage due to hepatitis C virus (HCV) infection were cured following a six-month course of therapy that combined an experimental drug, sofosbuvir, with the licensed antiviral drug ribavirin, in a study of an all-oral drug regimen. The results showed that the regimen was highly effective in clearing the virus and well tolerated in a group of patients who historically have had unfavorable prognoses. Scientists from the National ...
Labels:
Health News
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment